Modafinil

Generic Name: Modafinil

Brand Names: Provigil

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₅NO_₂S

CAS Number: 68693-11-8

Unique Ingredient Identifier: R3UK8X3U3D

Background: Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactiva...

Indication: To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.

Associated Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Fatigue, Major Depressive Disorder (MDD), Narcolepsy, Obstructive Sleep Apnea (OSA), Shift-work related sleep disturbance

Associated Therapies: -

Clinical Trials

Modafinil in Multiple Sclerosis

Not Applicable

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2005-09-02

Last Posted Date: 2013-09-26

Lead Sponsor: Kessler Foundation

Target Recruit Count: 20

Registration Number: NCT00142402

Locations: 🇺🇸
Kessler Foundation, West Orange, New Jersey, United States

Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence

Phase 2

Completed

Conditions: Alcohol-Related Disorders
Alcoholism
Cocaine-Related Disorders

Interventions: Drug: Naltrexone
Drug: Placebo
Drug: Modafinil

First Posted Date: 2005-09-02

Last Posted Date: 2020-07-16

Lead Sponsor: Kyle Kampman

Target Recruit Count: 164

Registration Number: NCT00142818

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

The Effects of Modafinil on Waking Function and on Sleep in Individuals With Primary Insomnia

Phase 4

Completed

Conditions: Primary Insomnia

First Posted Date: 2005-07-27

Last Posted Date: 2008-04-23

Lead Sponsor: University of Rochester

Target Recruit Count: 40

Registration Number: NCT00124384

Locations: 🇺🇸
University of Rochester Sleep and Neurophysiology Research Lab, Rochester, New York, United States

Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence

Phase 2

Conditions: Cocaine Dependence

First Posted Date: 2005-07-22

Last Posted Date: 2007-05-01

Lead Sponsor: The University of New South Wales

Target Recruit Count: 10

Registration Number: NCT00123383

Locations: 🇦🇺
Alcohol & Drug Services, St Vincent's Hospital, Darlinghurst, New South Wales, Australia
🇦🇺
Kirketon Road Centre, Sydney Hospital, Darlinghurst, New South Wales, Australia

Trial of Modafinil for Methamphetamine Dependence

Phase 2

Conditions: Amphetamine Dependence

First Posted Date: 2005-07-22

Last Posted Date: 2007-05-01

Lead Sponsor: The University of New South Wales

Target Recruit Count: 87

Registration Number: NCT00123370

Locations: 🇦🇺
Alcohol and Drug Services, St Vincent's Hospital, Darlinghurst, New South Wales, Australia
🇦🇺
Kirketon Road Centre, Darlinghurst, New South Wales, Australia

Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS

Phase 4

Completed

Conditions: HIV Infections
Fatigue

Interventions: Drug: Placebo
Drug: Modafinil

First Posted Date: 2005-07-11

Last Posted Date: 2017-05-10

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 115

Registration Number: NCT00118378

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Modafinil in Treating Fatigue in Patients With Cancer

Not Applicable

Conditions: Cognitive/Functional Effects
Depression
Fatigue
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2005-06-03

Last Posted Date: 2009-08-20

Lead Sponsor: University of Virginia

Registration Number: NCT00112515

Locations: 🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy

Phase 3

Completed

Conditions: Narcolepsy

First Posted Date: 2005-04-11

Last Posted Date: 2012-08-24

Lead Sponsor: Cephalon

Target Recruit Count: 140

Registration Number: NCT00107796

Locations: 🇺🇸
Joseph McCarty, M.D., Fort Smith, Arkansas, United States
🇺🇸
Anna Ivanenko, M.D., Ph.D., Maywood, Illinois, United States
🇺🇸
Carol Rosen, M.D., Cleveland, Ohio, United States

and more 69 locations

PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome

Phase 3

Completed

Conditions: Sleep Apnea, Obstructive
Narcolepsy

First Posted Date: 2005-04-11

Last Posted Date: 2014-05-09

Lead Sponsor: Cephalon

Target Recruit Count: 280

Registration Number: NCT00107848

Locations: 🇺🇸
Yury Furman, M.D., Los Angeles, California, United States
🇺🇸
Edward O'Malley, Norwalk, Connecticut, United States
🇺🇸
Gary Montgomery, M.D., Atlanta, Georgia, United States

and more 58 locations

Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome

Phase 3

Completed

Conditions: Sleep Apnea, Obstructive

First Posted Date: 2005-04-11

Last Posted Date: 2014-05-09

Lead Sponsor: Cephalon

Target Recruit Count: 140

Registration Number: NCT00107809

Locations: 🇺🇸
Lee Brooks, M.D., Princeton, New Jersey, United States
🇺🇸
D. Alan Lankford, Ph.D., Atlanta, Georgia, United States
🇺🇸
Gary Montgomery, M.D., Atlanta, Georgia, United States

and more 61 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy